The Global Health Body Issues Alert Over Critical Lack of Obesity Jabs
Fewer than 10% of people eligible to benefit from obesity jabs including Wegovy can access them, states the WHO as it releases its first guidance on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is calling for broader and more equitable availability to GLP-1 medication.
According to estimates, more than two billion could be obese by 2030 if no action is taken.
"The new guidance affirms that excess weight is a lifelong illness that can be managed with comprehensive and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are significant hurdles to widespread availability to the injections that can assist patients in reducing significant weight, explains the organization.
Skinny Jab Shortage
Even under the present most optimistic scenario, the manufacturing of such drugs could only cover approximately 100 million people – under 10% of eligible patients, according to the WHO.
The recommendation calls on countries and companies to widen availability, through strategies like licensing agreements.
A patent on the active ingredient – the core component of a leading brand – is set to lapse in several countries in 2026.
How Obesity Injections Function
GLP-1 drugs imitate a biological compound to delay gastric emptying, curb appetite and increase satiety so users consume fewer calories.
Individuals commonly begin shedding pounds after several weeks of starting on the once-weekly jabs.
Research points to users may see weight return after a year of discontinuing the medication, as their usual appetite return.
To be carrying excess weight raises your risk for experiencing medical conditions, such as type 2 diabetes, heart disease, stroke, and some malignancies.
Excess weight affects people in countries worldwide and was responsible for millions of deaths worldwide in 2024, as per the health agency.